Skip to main content

Invokana Plaintiffs To Submit Documents For Pending Claims

Invokana Plaintiffs To Submit Documents For Pending Claims

Invokana Plaintiffs To Submit Documents For Pending Claims

Introduction

In an order issued on August 16, Judge Martinotti presiding over Invokana lawsuits, instructed the plaintiffs whose claims remain unresolved to submit additional information related to their case. For proceeding, the plaintiffs are also required to inform the treating doctors and dispensing pharmacies to save evidence, medical records and fact sheets related to their claims. The order also implies that the resolution process would come into effect immediately for new Invokana cases filed. However, existing plaintiffs get time till October 30 for submitting the additional documents and evidence.

Defendants Johnson & Johnson and its subsidiary Janssen Pharmaceuticals face hundreds of lawsuits claiming the manufacturers failed to send out an adequate public warning regarding the risk of amputations of the leg and foot as potential side effects of the diabetes drug. The federal multidistrict litigation (MDL No: 2750) for Invokana lawsuits was formed in December 2016, in the U.S. District Court, District of New Jersey, presided by Hon. Brian R. Martinotti for coordinated pretrial proceedings. The first bellwether trial is slated to begin in September 2018.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Attorneys Seek Reconsideration of Talc MDL Daubert Ruling

Categories: General

Plaintiffs’ attorneys are urging the U.S. District Judge overseeing the talcum powder lawsuit MDL to reconsider a recent decision for a second round…

Philips resolves DreamStation suits for $1.1B

Categories: Settlements

Dutch medical technology company Philips has finalized a $1.1 billion settlement in the United States to address lawsuits concerning faulty…

FDA OKs Generic OTC Naloxone Spray Approved by FDA

Categories: FDA Related

The FDA has granted approval for Amneal Pharmaceuticals to release a generic 4 mg naloxone hydrochloride nasal spray for over-the-counter (OTC) use, an announcement made in a press release.

Our Legal Drafting Services    
start @ $25 per hour.